 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
0 News |  |
- Lasvic Intravenous (lascufloxacin IV) / Kyorin
Clinical Effectiveness of Lascufloxacin Drip Infusion, A Novel Fluoroquinolone Antibiotic, for the Treatment of Patients With Elderly Pneumonia and Lung Abscess (San Diego Convention Center, Area L (Hall H, Ground Level)) - Mar 17, 2024 - Abstract #ATS2024ATS_9513;
These data suggested that intravenous administration of LSFX was effective for bacterial pneumonia, including lung abscess, and it appears to have broad antimicrobial activity and good tissue penetration into the lung.
- | Lasvic Intravenous (lascufloxacin IV) / Kyorin
Journal: Effectiveness of Drip Infusion of Lascufloxacin, a Novel Fluoroquinolone Antibiotic, for Patients with Pneumonia Including Chronic Lung Disease Exacerbations and Lung Abscesses. (Pubmed Central) - Mar 13, 2024
There were no severe adverse effects in any of the 55 patients. Based on these data, intravenous administration of LSFX seems effective for bacterial pneumonia, including chronic lung disease exacerbations and lung abscesses, and it appears to have broad antimicrobial activity and good tissue penetration into the lung.
- | Lasvic tablet (lascufloxacin oral) / Kyorin, Lasvic Intravenous (lascufloxacin IV) / Kyorin
Journal: Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol. (Pubmed Central) - Feb 24, 2023
NHCAP is a common pneumonia in clinical settings and a notable pneumonia whose mortality is high compared to community-acquired pneumonia. The present study showed the efficacy and safety of LSFX against NHCAP, which could lead to a larger number of therapeutic options for NHCAP.